Medherant Expands Team with Appointment of David Davies as Head of Development
News Mar 07, 2018
Medherant Ltd, a leader in next-generation transdermal drug delivery, is pleased to announce the appointment of a new senior executive, David Davies, as Head of Development. This appointment marks a significant expansion of the Company’s management team to support the business as it moves into clinical development of its ibuprofen TEPI Patch®.
David brings over 30 years’ experience in pharmaceutical and medical device product development, in both small and large pharmaceutical companies, as well as at a senior level in global contract research organisations. He has held a variety of development roles, most recently as Lead Consultant at DDPC Ltd for three years and prior to that as Chief Development Officer at Futura Medical plc, where he was responsible for growth and development of the product pipeline from ideation through to regulatory approvals. He was part of the senior management team that took the company through to its admission to AIM, helping to grow the company from angel investment to a market capitalisation of £50m. In his spare time David holds three voluntary directorships – with the clinical outsourcing trade association PCMG Ltd, the charity Ordinary 2 extraordinary Ltd, and with the Red Lion Group, a medical charity.
David Davies commented, “I am delighted to be joining Medherant at this exciting stage in the company’s growth and development. My previous experience, particularly working with topical gels at Futura Medical, will be useful in developing patch-based products at Medherant. I’m looking forward to working with the rest of the team to deliver value growth for our investors and novel, exciting and effective products for our customers.”
Sally Waterman, COO of Medherant, added, “We’re thrilled to welcome David to the Medherant team. His knowledge of all aspects of the drug development pathway, and his experience in developing internal and external teams to help deliver company growth, will be invaluable as Medherant moves to the next stage of its evolution.”
Medherant has completed non-clinical work on its lead product, ibuprofen TEPI Patch®, and is currently working with AdhexPharma to manufacture the product, ready for clinical trials.
A new method of selectively binding proteins to nanoparticles has been published. The nanoparticles automatically recognize specific peptides, i.e. small proteins, and enter into highly selective binding with them. Among the model peptides which the researchers examined were amyloids. The researchers hope that the mechanism they have discovered might provide a new approach to treating diseases in which such deposits occur, such as Alzheimer’s disease.READ MORE
International Conference on Clinical Trials & Pharmacovigilance
Feb 28 - Mar 01, 2019